nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»nogr-14Research ArticleЛЕКЦИЯLECTIONАБДОМИНАЛЬНАЯ БОЛЬ И НАРУШЕНИЕ СТУЛА, ОБУСЛОВЛЕННЫЕ ФУНКЦИОНАЛЬНЫМИ ЗАБОЛЕВАНИЯМИ У ДЕТЕЙ И ПОДРОСТКОВABDOMINAL PAIN AND IRREGULAR BOWEL MOVEMENT CAUSED BY FUNCTIONAL DISORDERS IN CHILDREN AND ADOLESCENTSКондюринаЕ. Г.KondyurinaE. G.noemail@neicon.ruОсипенкоМ. Ф.OsipenkoM. F.ngma@bk.ruБикбулатоваЕ. А.BikbulatovaE. A.noemail@neicon.ruЗеленскаяВ. В.ZelenskayaV. V.noemail@neicon.ruГБОУ ВПО «Новосибирский государственный медицинский университет Минздрава России»РоссияNovosibirsk state medical universityRussian Federation201620012016017478Copyright © Кондюрина Е.Г., Осипенко М.Ф., Бикбулатова Е.А., Зеленская В.В., 20162016Кондюрина Е.Г., Осипенко М.Ф., Бикбулатова Е.А., Зеленская В.В.Kondyurina E.G., Osipenko M.F., Bikbulatova E.A., Zelenskaya V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/14

Функциональные заболевания (ФЗ) желудочно-кишечного тракта у детей - это комбинации гастроинтестинальных симптомов, наличие которых не может быть объяснено структурными или биохимическими аномалиями. Выделено 2 категории ФЗ для детей младшего возраста и для детей и подростков. Чаще всего поводом обращения к врачу является абдоминальная боль, и у детей прежде всего, необходимо исключать причины, требующие хирургического вмешательства. Наиболее часто у детей и подростков боли могут быть проявлением синдрома раздраженного кишечника, диспепсии, абдоминальной мигрени, функциональной абдоминальной боли и синдрома функциональной абдоминальной боли. Кроме боли предметом обращения могут стать запоры у детей. В фармакотерапии ФЗ у детей и подростков наиболее убедительно себя зарекомендовали спазмолитики и антидепрессанты, немедикаментозные методы.

Functional diseases (FD) of the gastrointestinal tract in children - a combination of gastrointestinal symptoms, the presence of which can not be explained by structural or biochemical abnormalities. Emphasis FD 2 categories for young children and for children and adolescents. The most common reason for seeking medical attention is abdominal pain, and children above all, necessary to exclude reason, requiring surgery. The most commonly in children and adolescents pain can be a manifestation of irritable bowel syndrome, dyspepsia, abdominal migraine, functional abdominal pain syndrome and functional abdominal pain. Also the subject of pain treatment can be constipation in children. In treatment in children and adolescents most convincingly proven antispasmodics and antidepressants, non-pharmacological methods.

функциональные заболеваниядети и подросткисиндром раздраженного кишечникаабдоминальная больFunctional diseaseschildren and adolescentsirritable bowel syndromeabdominal painReferencesEl-Radhi A. S. Management of abdominal pain in children. Br J Nurs. 2015; 24(1):44-7.El-Radhi A. S. Management of abdominal pain in children. Br J Nurs. 2015; 24(1):44-7.Bhupinder K. S., Siba P. Irritable bowel syndrome in children: Pathogenesis, Diagnosis and evidence-based treatment. World J Gastroenterol 2014; 20: 6013-6023.Bhupinder K. S., Siba P. Irritable bowel syndrome in children: Pathogenesis, Diagnosis and evidence-based treatment. World J Gastroenterol 2014; 20: 6013-6023.Rutten J. M., Benninga M. A., Vlieger A. M. IBS and FAPS in children: a comparison of psychological and clinical characteristics. J Pediatr Gastroenterol Nutr. 2014;59(4):493-9.Rutten J. M., Benninga M. A., Vlieger A. M. IBS and FAPS in children: a comparison of psychological and clinical characteristics. J Pediatr Gastroenterol Nutr. 2014;59(4):493-9.Henstrom M., Zucchelli M., Soderhall C., Bergstrom A., Kere J., Melen E., Olen O., D’Amato M. NPSR1 polymorphisms influence recurrent abdominal pain in children: a population-based study. Neurogastroenterol Motil. 2014;26(10):1417-25.Henstrom M., Zucchelli M., Soderhall C., Bergstrom A., Kere J., Melen E., Olen O., D’Amato M. NPSR1 polymorphisms influence recurrent abdominal pain in children: a population-based study. Neurogastroenterol Motil. 2014;26(10):1417-25.Guzyeyeva G. V. Giardia lamblia infection in hospitalized children with irritable bowel syndrome and dyspepsia: a prospective study. Faseb J. 2009;980:5.Guzyeyeva G. V. Giardia lamblia infection in hospitalized children with irritable bowel syndrome and dyspepsia: a prospective study. Faseb J. 2009;980:5.Vázquez-Frias R., Gutierrez-Reyes G., Urban-Reyes M., Velazquez-Guadarrama N., Fortoul-van der Goes T. I., Reyes-Lopez A., Consuelo-Sanchez A. Proinflammatory and anti-inflammatory cytokine profile in pediatric patients with irritable bowel syndrome. Rev Gastroenterol Mex. 2015; 16: 0375-0906(15)00003-8.Vázquez-Frias R., Gutierrez-Reyes G., Urban-Reyes M., Velazquez-Guadarrama N., Fortoul-van der Goes T. I., Reyes-Lopez A., Consuelo-Sanchez A. Proinflammatory and anti-inflammatory cytokine profile in pediatric patients with irritable bowel syndrome. Rev Gastroenterol Mex. 2015; 16: 0375-0906(15)00003-8.Self M. M., Czyzewski D. I., Chumpitazi B. P., Weidler E. M., Shulman R. J. Subtypes of irritable bowel syndrome in children and adolescents. Clin Gastroenterol Hepatol. 2014;12 (9):1468-73.Self M. M., Czyzewski D. I., Chumpitazi B. P., Weidler E. M., Shulman R. J. Subtypes of irritable bowel syndrome in children and adolescents. Clin Gastroenterol Hepatol. 2014;12 (9):1468-73.Phatak U. P., Pashankar D. S. Prevalence of functional gastrointestinal disorders in obese and overweight children. Int J Obes (Lond). 2014;38(10):1324-7.Phatak U. P., Pashankar D. S. Prevalence of functional gastrointestinal disorders in obese and overweight children. Int J Obes (Lond). 2014;38(10):1324-7.Chogle A., Mintjens S., Saps M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr Ann. 2014;43(4):76-82.Chogle A., Mintjens S., Saps M. Pediatric IBS: an overview on pathophysiology, diagnosis and treatment. Pediatr Ann. 2014;43(4):76-82.Huertas-Ceballos A., Logan S., Bennett C., Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003019.Huertas-Ceballos A., Logan S., Bennett C., Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003019.Paul S. P., Barnard P., Edate S., Candy D. C. Stool consistency and abdominal pain in irritable bowel syndrome may be improved by partially hydrolysed guargum. J Pediatr Gastroenterol Nutr. 2011;53:582-3.Paul S. P., Barnard P., Edate S., Candy D. C. Stool consistency and abdominal pain in irritable bowel syndrome may be improved by partially hydrolysed guargum. J Pediatr Gastroenterol Nutr. 2011;53:582-3.Chiou E, Nurko S. Management of functional abdominal pain and irritable bowel syndrome in children and adolescents. Expert Rev Gastroenterol Hepatol. 2010; 4:293-304.Chiou E, Nurko S. Management of functional abdominal pain and irritable bowel syndrome in children and adolescents. Expert Rev Gastroenterol Hepatol. 2010; 4:293-304.Huertas-Ceballos A., Logan S., Bennett C., Macarthur C., Martin A. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database of Systematic Reviews. 2014; 10.1002/14651856. CD003017.pub3.Huertas-Ceballos A., Logan S., Bennett C., Macarthur C., Martin A. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database of Systematic Reviews. 2014; 10.1002/14651856. CD003017.pub3.Hyun-Tai L., Byung J. K. Trimebutine as a Modulator of Gastrointestinal Motility. Arch Pharm 2011; 6:861-864.Hyun-Tai L., Byung J. K. Trimebutine as a Modulator of Gastrointestinal Motility. Arch Pharm 2011; 6:861-864.Brandt L. J., Chey W. D., Foxx-Orenstein A. E., Schiller L. R., Schoenfeld P. S., Spiegel B. M., Talley N. J., Quigley E. M. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (1): 1-35.Brandt L. J., Chey W. D., Foxx-Orenstein A. E., Schiller L. R., Schoenfeld P. S., Spiegel B. M., Talley N. J., Quigley E. M. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (1): 1-35.Talley N. J. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 750-758.Talley N. J. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003; 98: 750-758.Brandt L. J., Bjorkman D., Fennerty M. B., Locke G. R., Olden K., Peterson W., Quigley E., Schoenfeld P., Schuster M., Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: 7-26.Brandt L. J., Bjorkman D., Fennerty M. B., Locke G. R., Olden K., Peterson W., Quigley E., Schoenfeld P., Schuster M., Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: 7-26.Pimentel M., Lembo A., Chey W. D., Zakko S., Ringel Y., Yu J., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.Pimentel M., Lembo A., Chey W. D., Zakko S., Ringel Y., Yu J., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.Giorgio V., D’ Andrea V., Coccia P., Filoni S., Rendeli C., Fundaro C. Efficacy of rifaximin for SIBO treatment in IBS children. Pediatr. Res. 2010;68:144.Giorgio V., D’ Andrea V., Coccia P., Filoni S., Rendeli C., Fundaro C. Efficacy of rifaximin for SIBO treatment in IBS children. Pediatr. Res. 2010;68:144.Tojo Gonzalez R., Suarez Gonzalez A., Ruas Madiedo P., Mancebo Mata A. Pipa Muniz M., Barreiro Alonso E., Roman Llorente F. J., Moro Villar M. C., Arce Gonzalez M. M., Villegas Diaz M. F., Mosquera Sierra E., Ruiz Ruiz M. Irritable Bowel Syndrome; gut microbiota and probiotic therapy. Nutr Hosp. 2015; 3(1):83-8.Tojo Gonzalez R., Suarez Gonzalez A., Ruas Madiedo P., Mancebo Mata A. Pipa Muniz M., Barreiro Alonso E., Roman Llorente F. J., Moro Villar M. C., Arce Gonzalez M. M., Villegas Diaz M. F., Mosquera Sierra E., Ruiz Ruiz M. Irritable Bowel Syndrome; gut microbiota and probiotic therapy. Nutr Hosp. 2015; 3(1):83-8.Rutten J. M., Reitsma J. B., Vlieger A. M., Vlieger A. M., Benniga M. A. Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review. Arch Dis Child. 2013; 98:252-7.Rutten J. M., Reitsma J. B., Vlieger A. M., Vlieger A. M., Benniga M. A. Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review. Arch Dis Child. 2013; 98:252-7.Krogsbоll LT, Hróbjartsson A, Gоtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol. 2009;9:1.Krogsbоll LT, Hróbjartsson A, Gоtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol. 2009;9:1.Merat S., Khalili S., Mostajabi P., Ghorbani A., Ansari R., Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55: 1385-1390.Merat S., Khalili S., Mostajabi P., Ghorbani A., Ansari R., Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55: 1385-1390.

The authors declare that there are no conflicts of interest present.